dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Hollebecque, Antoine |
dc.contributor.author | Salvagni, Stefania |
dc.contributor.author | Plummer, Ruth |
dc.contributor.author | Niccoli, Patricia |
dc.contributor.author | Capdevila Castillon, Jaume |
dc.contributor.author | Curigliano, Giuseppe |
dc.date.accessioned | 2022-09-12T09:40:12Z |
dc.date.available | 2022-09-12T09:40:12Z |
dc.date.issued | 2022-09-01 |
dc.identifier.citation | Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, et al. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185–95. |
dc.identifier.issn | 1097-0142 |
dc.identifier.uri | https://hdl.handle.net/11351/8150 |
dc.description | Tumor neuroendocrí; Limfoma no Hodgkin; Inhibidor de la desmetilasa-1 específica a la lisina |
dc.description.sponsorship | This study was supported by Bristol Myers Squibb, Princeton, New Jersey, USA. Writing and editorial assistance was provided by Bio Connections, LLC, funded by Bristol Myers Squibb. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer;128(17) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Posologia |
dc.subject | Càncer - Tractament |
dc.subject | Medicaments - Eficàcia |
dc.subject.mesh | Maximum Tolerated Dose |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Lymphoma, B-Cell, Marginal Zone |
dc.subject.mesh | Histone Demethylases |
dc.title | Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cncr.34366 |
dc.subject.decs | dosis máxima tolerada |
dc.subject.decs | neoplasias |
dc.subject.decs | linfoma de células B de la zona marginal |
dc.subject.decs | histona desmetilasas |
dc.relation.publishversion | https://doi.org/10.1002/cncr.34366 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Hollebecque A] Gustave Roussy, Département d’innovation thérapeutique et essais précoces, Villejuif, France. [Salvagni S] S. Orsola Polyclinic, Malpighi University Hospital, Bologna, Italy. [Plummer R] Clinical and Translational Research Institute Northern, Newcastle University, Newcastle, UK. [Niccoli P] Department of Medical Oncology, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France. [Capdevila J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. IOB-Teknon, Barcelona, Spain. [Curigliano G] European Institute of Oncology, IRCCS, University of Milan, Milan, Italy |
dc.identifier.pmid | 35737639 |
dc.identifier.wos | 000814787400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |